Press Releases July 1, 2026 09:00 AM

Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29

Chemed Corporation announces Q2 2026 earnings release and conference call dates

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
CHE

Chemed Corporation will report its Q2 2026 financial results on July 28, 2026, after market close, followed by a conference call and webcast on July 29, 2026, to discuss the results and provide a business update. The company operates two main subsidiaries: VITAS Healthcare, a leading hospice care provider, and Roto-Rooter, a leading plumbing and drain cleaning service provider.

Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29
CHE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Chemed plans to announce Q2 2026 earnings on July 28, 2026, with a webcasted conference call on July 29.
  • The company operates in healthcare (hospice care via VITAS Healthcare) and home services (plumbing via Roto-Rooter).
  • Forward-looking statements highlight potential risks and uncertainties in future performance.

CINCINNATI, July 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2026, on Tuesday, July 28, 2026, following the close of trading on the New York Stock Exchange.

Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, July 29, 2026, to discuss the company's quarterly results and to provide an update on its business.

Participants may access a live webcast of the conference call through the investor relations section of Chemed’s website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media-server.com/mmc/p/u8u2qjst.

Participants may also register via teleconference at https://register-conf.media-server.com/register/BI55b09312fbd04f76b526dfcc5f7e174e.

Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.

A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed’s website.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

CONTACT: Michael D. Witzeman (513) 762-6714  

Risks

  • Forward-looking statements are subject to inherent risks that actual results may materially differ.
  • Potential uncertainties in operating business segments, including healthcare and home services.
  • No guarantee that earnings results meet or exceed market expectations.

More from Press Releases

GSR V Acquisition Corp. Announces the Separate Trading of its Shares of Class A Ordinary Shares and Commencing July 2, 2026 Jul 1, 2026 High Income Securities Fund Announces Monthly Distributions For Third Quarter of 2026 Jul 1, 2026 Provident Financial Services, Inc. Schedules Second Quarter Earnings Conference Call Jul 1, 2026 Tenable Named as the Current Company to Beat for AI-Powered Exposure Assessment in a June 2026 Gartner® Report Jul 1, 2026 NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes Jul 1, 2026